Sodium oxalate,ACS,99.5%
Based on 1 Customer Validation
Sodium oxalate is an orally active dispersant and coordination agent. Sodium oxalate causes mitochondrial dysfunction. Sodium oxalate has catalytic enhancing activity. Sodium oxalate induces stable chronic kidney disease. Sodium oxalate induces highly malignant and undifferentiated breast tumors.
For research use only. We do not sell to patients.
- Purity: 99.65%
- CAS No.: 62-76-0
- Formula: NaOOCCOONa
- Molecular Weight:134.00
-
Storage:
Store at room temperature, keep dry and cool.
In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-13966
2-Deoxy-D-glucose
-
HY-W040233
L-Lactic acid sodium
-
HY-Y0479
L-Lactic acid
-
HY-Y0344D
Sodium chloride, for cell culture
-
HY-B2227B
Lactic acid sodium (60% w/w in water)
-
HY-Y0344I
Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al
-
HY-Y0344J
Sodium chloride, for molecular biology
-
HY-Y0308E
Sodium phosphate dibasic, for cell culture
-
HY-Y0308
Disodium phosphate
-
HY-Y0682A
Ethylenediaminetetraacetic acid disodium dihydrate
-
HY-Y0308H
Sodium phosphate dibasic, for molecular biology
-
HY-B1820
Zinc sulphate
Biological Activity
Sodium oxalate (1-4 mM; 1-24 h) leads to time- and concentration-dependent decrease in cell survival, inhibits proliferation in LLCPK1, MDCK, renal fibroblast and endothelial cells[2].
Sodium oxalate (0.1-2 mM; 24 h) causes mitochondrial dysfunction, reduces basal OCR and ATP-linked OCR in THP-1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Sodium oxalate (Oxalic acid form; 0.5 mmol/kg; i.p.; once daily for 5 consecutive days) combined with DMSA reverses GaAs-induced oxidative stress, reducing arsenic and gallium levels in tissues of male Wistar albino rats[6].
Sodium oxalate (50 μmol/g in calcium-free diet; p.o.) induces stable chronic kidney disease in C57BL/6 mice[7].
Sodium oxalate (70 mg/kg body weight; p.o. in drinking water; 30 days) induces urolithiasis in male mice, increasing serum uric acid, creatinine, sodium, phosphate, oxalate levels and renal sodium, phosphate, oxalate deposition [8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male and female C57BL/6 mice (8-12 weeks old); chronic kidney disease model[7]
-
Dosage:50 μmol/g in calcium-free standard diet
-
Administration:Oral administration via diet
-
Result:Caused phenotypes including tubular damage, interstitial inflammation, and fibrosis, with complications such as anemia, hyperphosphatemia, and hypertension.
Chemical Information
-
CAS No. 62-76-0
-
Appearance Solid
-
Molecular Weight 134.00
-
Formula NaOOCCOONa
-
Color White to off-white
-
SMILES
O=C(O[Na])C(O[Na])=O
-
Synonyms
Ethanedioic acid sodium,ACS, 99.5%
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature, keep dry and cool
In solvent -80°C 1 year -20°C 6 months
Solvent & Solubility
H2O : 5 mg/mL (37.31 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 16.67 mg/mL (124.40 mM); Clear solution; Need ultrasonic
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[2]. Knoll T, et al. The influence of oxalate on renal epithelial and interstitial cells. Urol Res. 2004 Aug;32(4):304-9. [Content Brief]
[3]. Patel M, et al. Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line. Redox Biol. 2018 May;15:207-215. [Content Brief]
[4]. Castellaro AM, et al. Oxalate induces breast cancer. BMC Cancer. 2015 Oct 22;15:761. [Content Brief]
[5]. Heller A, et al. Oxalic acid has an additional, detoxifying function in Sclerotinia sclerotiorum pathogenesis. PLoS One. 2013 Aug 12;8(8):e72292. [Content Brief]
[6]. Flora SJ, et al. Combined administration of oxalic acid, succimer and its analogue for the reversal of gallium arsenide-induced oxidative stress in rats. Arch Toxicol. 2002 Jun;76(5-6):269-76. [Content Brief]
[7]. Mulay SR, et al. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. Am J Physiol Renal Physiol. 2016 Apr 15;310(8):F785-F795. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 7.4627 mL | 37.3134 mL | 74.6269 mL | 186.5672 mL |
| 5 mM | 1.4925 mL | 7.4627 mL | 14.9254 mL | 37.3134 mL | |
| 10 mM | 0.7463 mL | 3.7313 mL | 7.4627 mL | 18.6567 mL | |
| 15 mM | 0.4975 mL | 2.4876 mL | 4.9751 mL | 12.4378 mL | |
| 20 mM | 0.3731 mL | 1.8657 mL | 3.7313 mL | 9.3284 mL | |
| 25 mM | 0.2985 mL | 1.4925 mL | 2.9851 mL | 7.4627 mL | |
| 30 mM | 0.2488 mL | 1.2438 mL | 2.4876 mL | 6.2189 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Sodium oxalate,ACS,99.5% Related Classifications
HY-Y0262B Related Classifications
Powered by Bioz